{"product_id":"inbs-marketing-mix","title":"(INBS) Intelligent Bio Solutions Inc. Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Intelligent Bio Solutions Inc. 4P's Marketing Mix Analysis explains the company’s product offering, pricing approach, distribution channels, and promotional tactics in a concise, actionable format; the page includes a real preview\/sample of the report so you can review style and content before buying—purchase the full version to download the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-invasive diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntelligent Bio Solutions Inc.’s non-invasive diagnostics focus on biosensor-based, real-time testing for patients and primary care teams, not consumer gadgets. The product fit is clear in medical diagnostics, where quicker results can cut clinic delays and avoid invasive sampling. In its latest reported FY2025 period, the company remained in a development-led phase, so product value rests on clinical utility, adoption, and reimbursement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSaliva Glucose Biosensor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntelligent Bio Solutions Inc.’s Saliva Glucose Biosensor is an organic thin-film transistor built to measure glucose in saliva, giving diabetes care a non-invasive testing option. The market need is large: the International Diabetes Federation estimated 589 million adults with diabetes worldwide in 2024. That scale supports a product pitch built on convenience, lower user pain, and repeat testing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSARS-CoV-2 Biosensor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntelligent Bio Solutions Inc. is developing a SARS-CoV-2 Biosensor as a supplementary diagnostic tool alongside RNA virus detection methods, keeping its product mix tied to infectious-disease testing. WHO has reported more than 776 million confirmed COVID-19 cases worldwide, which shows why faster screening tools still matter. The product supports the company’s portfolio breadth while targeting a market that remains clinically relevant.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMulti-analyte platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntelligent Bio Solutions Inc.'s multi-analyte platform is built to cover biochemistry, immunology, tumor markers, hormones, and nucleic acid tests in one biosensor stack. That platform model can widen test-menu reach without building a new system for each assay, which helps scale product use across more labs and point-of-care settings.\u003c\/p\u003e\n\u003cp\u003eFor the Product \"P\", this matters because one platform can support multiple diagnostic categories and lower the cost of adding new tests. The company has not published 2025 or 2026 platform revenue split in the materials available here, so the key metric is breadth of test coverage, not disclosed sales mix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMultiple diagnostic modalities\u003c\/li\u003e\n\u003cli\u003eSupports category expansion\u003c\/li\u003e\n\u003cli\u003eSingle platform, broader menu\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003e2016 origin, 2022 rebrand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntelligent Bio Solutions Inc. was incorporated in 2016, then rebranded from GBS Inc. in October 2022 to match a wider biosolution identity. That shift sharpened the product story for 4P analysis: a newer, science-led company with a clearer market position. \u003c\/p\u003e\n\u003cp\u003eThe name change helped move the brand from a narrow legacy label to a broader platform built around bio-based testing and diagnostics. In a market where trust and clarity drive adoption, the 2022 rebrand became a key marketing signal. \u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIncorporated: 2016\u003c\/li\u003e\n\u003cli\u003eFormer name: GBS Inc.\u003c\/li\u003e\n\u003cli\u003eRebrand date: October 2022\u003c\/li\u003e\n\u003cli\u003eBrand scope: broader biosolution identity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-Invasive Biosensors Targeting Diabetes and Infectious Disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntelligent Bio Solutions Inc.’s Product mix is a development-stage biosensor platform led by non-invasive diagnostics, with saliva glucose and SARS-CoV-2 tests plus a multi-analyte stack for broader assay coverage. The pitch is simple: less pain, faster screening, and easier repeat testing in clinical settings.\u003c\/p\u003e\n\u003cp\u003eIts core product case is scale, not current revenue; the International Diabetes Federation estimated 589 million adults with diabetes in 2024, and WHO has reported more than 776 million confirmed COVID-19 cases worldwide.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eUse case\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSaliva Glucose Biosensor\u003c\/td\u003e\n\u003ctd\u003eDiabetes testing\u003c\/td\u003e\n\u003ctd\u003eNon-invasive\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSARS-CoV-2 Biosensor\u003c\/td\u003e\n\u003ctd\u003eInfectious-disease screening\u003c\/td\u003e\n\u003ctd\u003eSupplementary tool\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform\u003c\/td\u003e\n\u003ctd\u003eMulti-analyte testing\u003c\/td\u003e\n\u003ctd\u003eBiochemistry, immunology, tumor markers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise, company-specific 4P analysis of Intelligent Bio Solutions Inc.’s product, pricing, placement, and promotion strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eClarifies Intelligent Bio Solutions Inc.’s 4Ps at a glance, easing quick decisions and stakeholder alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise bibliography linking each key claim to reputable industry reports, gov datasets, and benchmarks to speed due diligence and verify assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew York headquarters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntelligent Bio Solutions Inc. is based in New York, New York, and that city is its corporate base. New York sits in a top U.S. life sciences and capital markets hub, with direct access to investors, talent, and partners. That location supports funding, visibility, and faster business development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSubsidiary structure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntelligent Bio Solutions Inc. operates under Life Science Biosensor Diagnostics Pty Ltd, a parent-subsidiary setup that centralizes governance while keeping product work close to operations. In fiscal 2025, the group reported revenue of $4.6 million, showing how the structure supports development and commercial control across the business. One clear upside: tighter oversight can speed decisions and limit duplicate costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare provider focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntelligent Bio Solutions Inc. targets two user groups: patients and their primary healthcare providers. That puts its products in a healthcare distribution channel, not general retail, so access depends on clinics and care settings. This setup usually means slower rollout than store sales, but stronger clinical trust and repeat use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical diagnostics channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical diagnostics is the main route to market for Intelligent Bio Solutions Inc., because its products are built for medical testing and lab use. In 2025\/2026, this channel favors adoption through hospitals, clinics, and reference labs, where regulated workflows and reimbursement matter most. The mix fits healthcare buyers that want fast, repeatable results and low training burden.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHospital and lab sales drive access\u003c\/li\u003e\n\u003cli\u003eRegulation supports trust and adoption\u003c\/li\u003e\n\u003cli\u003eReimbursement helps repeat buying\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePublic channel details limited\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntelligent Bio Solutions Inc. does not publish a detailed retail channel map, so its public channel details stay limited. The company’s filings focus on development and intended medical use, and specific market-by-market placement terms are not broadly disclosed.\u003c\/p\u003e\n\u003cp\u003eThat makes the Place mix hard to pin down from public data alone, with no disclosed 2025\/2026 retail rollout split or channel revenue by geography.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLimited retail placement disclosure\u003c\/li\u003e\n\u003cli\u003eFocus on medical-use development\u003c\/li\u003e\n\u003cli\u003eNo market-level channel map\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntelligent Bio Solutions’ Narrow Channel Focus Limits Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntelligent Bio Solutions Inc. keeps Place tight: New York is the corporate base, while medical diagnostics distribution centers on hospitals, clinics, and labs. In fiscal 2025, revenue was $4.6 million, but the company did not disclose a 2026\/2025 retail rollout map or channel split. That limited disclosure means access depends more on regulated care settings than broad consumer reach.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace factor\u003c\/th\u003e\n\u003cth\u003e2025\/2026 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCorporate base\u003c\/td\u003e\n\u003ctd\u003eNew York, New York\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMain channel\u003c\/td\u003e\n\u003ctd\u003eHospitals, clinics, labs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 revenue\u003c\/td\u003e\n\u003ctd\u003e$4.6 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDisclosure\u003c\/td\u003e\n\u003ctd\u003eNo retail map disclosed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eIntelligent Bio Solutions Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis preview is the actual, full Intelligent Bio Solutions Inc. 4P’s Marketing Mix analysis you’ll receive instantly after purchase—no sample or demo, fully editable and ready to use for strategy, presentations, or investor review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNasdaq: INBS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntelligent Bio Solutions Inc. trades on Nasdaq as INBS, so its promotion must follow public-company disclosure rules. That means investor materials, 10-K and 10-Q filings, and earnings updates shape the brand story. Public listing also boosts visibility, with one ticker symbol used across market news, investors, and customer outreach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePress releases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntelligent Bio Solutions Inc. uses press releases to package product, regulatory, and partnership news in one clear channel. In FY2025, this matters because biosensor companies need fast proof points, not broad ads, to build trust. One release can reach investors, customers, and partners at the same time.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvestor relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInvestor relations is a key promotion channel for Intelligent Bio Solutions Inc., helping explain strategy, product updates, and funding needs to analysts and shareholders. Public life sciences firms use this channel to cut information gaps and build trust, which matters when cash burn and R\u0026amp;D spending drive valuation. For a micro-cap like Intelligent Bio Solutions Inc., steady IR updates can lift awareness around milestones, revenue progress, and capital raises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eWebsite-led messaging\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntelligent Bio Solutions Inc. should use its website as the main place to explain product features, clinical value, and where its diagnostics fit in the market. For diagnostics buyers, this is where product positioning and proof points belong, alongside clear company facts. The site should also host investor materials, since public companies with $0.0? No, avoid fake numbers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExplain clinical value clearly\u003c\/li\u003e\n\u003cli\u003eShow product positioning fast\u003c\/li\u003e\n\u003cli\u003eCentralize structured company data\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eScientific outreach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eScientific outreach is a key Promotion lever for Intelligent Bio Solutions Inc. because its biosensor and diagnostic tech needs trust from healthcare and research buyers. Sharing how the platform works helps turn technical proof into market awareness, which matters in a 2025 addressable market already shaped by faster, non-invasive testing demand.\u003c\/p\u003e\n\u003cp\u003eIt also supports credibility with clinicians, lab teams, and academic users, where evidence beats hype. One clear message: if the science is strong, the communication has to be just as sharp.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBuild trust through technical education\u003c\/li\u003e\n\u003cli\u003eReach healthcare and research audiences\u003c\/li\u003e\n\u003cli\u003eTurn science into brand awareness\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompliance-First Promotion Builds Trust at Intelligent Bio Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePromotion at Intelligent Bio Solutions Inc. is built around compliance-first investor communication, press releases, and scientific outreach, not mass-market ads. As a Nasdaq-listed micro-cap, it uses 10-K and 10-Q filings plus IR updates to explain product milestones and funding needs. That matters because one clear channel can reach investors, customers, and partners at once.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eCount\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFilings\u003c\/td\u003e\n\u003ctd\u003eInvestor disclosure\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePress releases\u003c\/td\u003e\n\u003ctd\u003eNews packaging\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore focus\u003c\/td\u003e\n\u003ctd\u003eTrust building\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo public list price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntelligent Bio Solutions Inc. does not show a public list price, so buyers cannot compare it like an off-the-shelf product. The company’s public materials focus on product development and commercialization, not posted pricing, which points to a quote-based sales model. That fits a B2B setup where pricing is set case by case instead of open shelf pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSaliva Glucose price undisclosed\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSaliva Glucose Biosensor price is undisclosed, and Intelligent Bio Solutions Inc. has shared the product’s clinical purpose, not a list price. That usually means pricing will be set later, based on approval stage, test volume, and whether it is sold to hospitals, labs, or direct customers. Until a launch date and reimbursement path are public, there is no reliable market price to quote.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSARS-CoV-2 price undisclosed\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntelligent Bio Solutions Inc. does not publish a price for the SARS-CoV-2 Biosensor. The product is still described as a supplementary diagnostic tool, so formal pricing has not been set in public materials. That means buyers cannot compare list price, margin, or reimbursement terms from disclosed data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEnterprise-style pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntelligent Bio Solutions Inc. appears to use enterprise-style pricing, where diagnostic and biosensor products are sold through negotiated contracts, not consumer checkout. That fits a healthcare model tied to clinical adoption, reimbursement, and site volume. Public filings through FY2025\/FY2026 do not disclose contract rates, discount terms, or price lists.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNegotiated, not posted, pricing\u003c\/li\u003e\n\u003cli\u003eLinked to clinical adoption\u003c\/li\u003e\n\u003cli\u003eNo public contract-rate disclosure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eValue-based positioning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntelligent Bio Solutions Inc. prices on value, not cheapness: its non-invasive drug testing is built around faster results and easier use, which is the real economic pitch. Public materials point to clinical utility and convenience, with results in under 5 minutes, so the buyer case is less about unit price and more about time saved and fewer workflow breaks.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUnder 5-minute testing supports speed.\u003c\/li\u003e\n\u003cli\u003eNon-invasive use lowers friction.\u003c\/li\u003e\n\u003cli\u003eValue beats price competition here.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFast, Negotiated Pricing Powers Intelligent Bio Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntelligent Bio Solutions Inc. uses quote-based pricing, not posted list prices, so Price in its 4P mix is driven by contract terms, test volume, and adoption stage. Public FY2025\/FY2026 materials still disclose no contract rates or discounts. The value case is speed and ease of use: results in under 5 minutes.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePrice signal\u003c\/th\u003e\n\u003cth\u003ePublic data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eList price\u003c\/td\u003e\n\u003ctd\u003eUndisclosed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eModel\u003c\/td\u003e\n\u003ctd\u003eNegotiated B2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResult time\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5 minutes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234592071945,"sku":"inbs-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/inbs-marketing-mix.webp?v=1785721911","url":"https:\/\/dcfanalyst.com\/products\/inbs-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}